Haleon PLC (HLN) - Net Assets

Latest as of June 2025: GBX16.00 Billion GBX ≈ $1.95 Million USD

Based on the latest financial reports, Haleon PLC (HLN) has net assets worth GBX16.00 Billion GBX (≈ $1.95 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX31.83 Billion ≈ $3.87 Million USD) and total liabilities (GBX15.83 Billion ≈ $1.93 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Haleon PLC (HLN) asset resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX16.00 Billion
% of Total Assets 50.26%
Annual Growth Rate -9.95%
5-Year Change -38.13%
10-Year Change N/A
Growth Volatility 14.84

Haleon PLC - Net Assets Trend (2019–2024)

This chart illustrates how Haleon PLC's net assets have evolved over time, based on quarterly financial data. Also explore Haleon PLC total assets for the complete picture of this company's asset base.

Annual Net Assets for Haleon PLC (2019–2024)

The table below shows the annual net assets of Haleon PLC from 2019 to 2024. For live valuation and market cap data, see Haleon PLC market capitalisation.

Year Net Assets Change
2024-12-31 GBX16.22 Billion
≈ $1.97 Million
-3.02%
2023-12-31 GBX16.73 Billion
≈ $2.04 Million
+1.65%
2022-12-31 GBX16.46 Billion
≈ $2.00 Million
-37.85%
2021-12-31 GBX26.48 Billion
≈ $3.22 Million
+0.98%
2020-12-31 GBX26.22 Billion
≈ $3.19 Million
-4.34%
2019-12-31 GBX27.41 Billion
≈ $3.34 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Haleon PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 434.1% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings GBX27.27 Billion 168.70%
Common Stock GBX91.00 Million 0.56%
Other Comprehensive Income GBX-11.08 Billion -68.55%
Total Equity GBX16.17 Billion 100.00%

Haleon PLC Competitors by Market Cap

The table below lists competitors of Haleon PLC ranked by their market capitalization.

Company Market Cap
Marshall Boya ve Vernik Sanayi AS
IS:MRSHL
$373.05 Million
TechTarget, Inc. Common Stock
NASDAQ:TTGT
$373.06 Million
Ningbo Heli Mould Technology Co Ltd Class A
SHG:603917
$373.15 Million
Tarczynski S.A.
WAR:TAR
$373.18 Million
Chalice Mining Limited
F:C8U
$372.83 Million
Saratoga Investment Corp
NYSE:SAR
$372.72 Million
Bafang Yunji Intl Co Ltd
TW:2753
$372.69 Million
Xuancheng Valin Precision Technology Co Ltd
SHG:603356
$372.68 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Haleon PLC's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 16,606,000,000 to 16,166,000,000, a change of -440,000,000 (-2.6%).
  • Net income of 1,442,000,000 contributed positively to equity growth.
  • Dividend payments of 570,000,000 reduced retained earnings.
  • Share repurchases of 619,000,000 reduced equity.
  • Other comprehensive income decreased equity by 121,000,000.
  • Other factors decreased equity by 572,000,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income GBX1.44 Billion +8.92%
Dividends Paid GBX570.00 Million -3.53%
Share Repurchases GBX619.00 Million -3.83%
Other Comprehensive Income GBX-121.00 Million -0.75%
Other Changes GBX-572.00 Million -3.54%
Total Change GBX- -2.65%

Book Value vs Market Value Analysis

This analysis compares Haleon PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 195.29x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 116.31x to 195.29x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2019-12-31 GBX2.96 GBX344.10 x
2020-12-31 GBX2.83 GBX344.10 x
2021-12-31 GBX2.85 GBX344.10 x
2022-12-31 GBX1.77 GBX344.10 x
2023-12-31 GBX1.79 GBX344.10 x
2024-12-31 GBX1.76 GBX344.10 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Haleon PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 8.92%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 12.84%
  • • Asset Turnover: 0.33x
  • • Equity Multiplier: 2.12x
  • Recent ROE (8.92%) is above the historical average (5.63%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2019 2.40% 7.72% 0.24x 1.31x GBX-2.08 Billion
2020 4.38% 11.58% 0.29x 1.31x GBX-1.47 Billion
2021 5.27% 14.56% 0.28x 1.31x GBX-1.25 Billion
2022 6.49% 9.76% 0.31x 2.13x GBX-573.10 Million
2023 6.32% 9.28% 0.33x 2.05x GBX-611.60 Million
2024 8.92% 12.84% 0.33x 2.12x GBX-174.60 Million

Industry Comparison

This section compares Haleon PLC's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $244,076,329
  • Average return on equity (ROE) among peers: -157.58%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Haleon PLC (HLN) GBX16.00 Billion 2.40% 0.99x $372.86 Million
Allergy Therapeutics (AGY) $7.08 Million 17.21% 0.59x $7.66 Million
Animalcare Group Plc (ANCR) $22.52 Million 11.70% 0.19x $2.79 Million
Alliance Pharma plc (APH) $16.63 Million 24.70% 2.42x $4.26 Million
Celadon Pharmaceuticals PLC (CEL) $99.03K -1412.59% 37.89x $112.25K
Chill Brands Group PLC (CHLL) $-1.23 Million 0.00% 0.00x $25.45K
Eco Animal Health Group Plc (EAH) $5.21 Million 12.52% 0.25x $763.17K
HUTCHMED China Ltd (HCM) $743.39 Million 13.56% 0.72x $20.39 Million
Hikma Pharmaceuticals PLC (HIK) $1.35 Billion 18.64% 0.92x $37.94 Million
Indivior PLC (INDV) $51.00 Million -103.92% 33.69x $18.79 Million

About Haleon PLC

LSE:HLN UK Drug Manufacturers - Specialty & Generic
Market Cap
$372.86 Million
GBX3.06 Trillion GBX
Market Cap Rank
#14010 Global
#65 in UK
Share Price
GBX344.10
Change (1 day)
+1.21%
52-Week Range
GBX326.60 - GBX415.20
All Time High
GBX415.20
About

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene… Read more